**Table of Contents**

[Supplementary Table 1. 2](#_Toc127791413)

[Supplementary Table 2 3](#_Toc127791414)

[Additional members of the ESTAMPA study group 4](#_Toc127791415)

**Supplementary Table 1.** Characteristics of study population. Mean (and standard deviation) or absolute frequency (and percentage) shown for quantitative and qualitative variables respectively.

|  |  |
| --- | --- |
| **Characteristics among women** | n = 30,606 (100%) |
| ***Age, years*** |   |
| Mean, years | 44·4 (±9·3) |
| 30-39 | 11,765 (38·4%) |
| 40-49 | 9,853 (32·2%) |
| 50-64 | 8,988 (29·4%) |
| ***Last pap smear done*** |   |
| Less than 2 years ago | 15,286 (50·0%) |
| 2-5 years ago | 10,847 (35·5%) |
| >5 years ago | 3,808 (12·5%) |
| Never | 607 (2·0%) |
| Missing information | 58 |
|   |   |
| **Characteristics among study centres** |   |
| ***Study centres***  |   |
| Argentina 1 |  3,312 (10·8%) |
| Argentina 2 |  320 (1·0%) |
| Bolivia  |  3,155 (10·3%) |
| Colombia 2 |  1,219 (4·0%) |
| Costa Rica |  8,548 (27·9%) |
| Honduras |  4,129 (13·5%) |
| México |  804 (2·6%) |
| Paraguay 1 |  6,239 (20·4%) |
| Paraguay 2 |  367 (1·2%) |
| Perú |  658 (2·1%) |
| Uruguay |  1,855 (6·1%) |

**Supplementary Table 2**. Performance of cytology and HPV testing to detect CIN3+ and CIN2+ diagnosed at enrolment and/or 18-months. Estimates with 95% confidence intervals shown.

|  |  |  |  |
| --- | --- | --- | --- |
|   | **Cytology** |   | **HPV** |
|   |   |   |   |
| **Performance characteristics** |   |   |   |
| ***CIN3+*** |   |   |   |
| Sensitivity | 45·6% (41·3-50·0) |   | 97·9% (96·3-98·9) |
| Specificity | 97·5% (97·4-97·7) |   | 91·7% (91·4-92·0) |
| PPV | 24·5% (21·8-27·3) |   | 17·0% (15·6-18·3) |
| cNPV | 1·0% (0·9-1·1) |   | 0·04% (0·02-0·07) |
| TP | 243 |   | 522 |
| FP | 709 |   | 2,394 |
| TN | 28,064 |   | 26,379 |
| FN | 290 |   | 11 |
|   |   |   |   |
| ***CIN2+*** |   |   |   |
| Sensitivity | 40·3% (36·6-44·0) |   | 97·3% (95·8-98·4) |
| Specificity | 97·5% (97·4-97·7) |   | 91·7% (91·4-92·0) |
| PPV | 28·6% (25·8-31·5) |   | 22·3% (20·8-23·8) |
| cNPV | 1·5% (1·3-1·6) |   | 0·07% (0·04-0·11) |
| TP | 284 |   | 686 |
| FP | 709 |   | 2,394 |
| TN | 28,064 |   | 26,379 |
| FN | 421 |   | 19 |

**Additional members of the ESTAMPA study group:**

María de la Luz Hernández, SMS-Oncology, Amsterdam, The Netherlands.

Mary Luz Rol, Eric Lucas, Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France

Raul Murillo, Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia

Jose Jerónimo, Liga contra el Cáncer-Perú, Lima, Perú. US National Cancer Institute, Bethesda, MD, USA

Catterina Ferreccio, Advanced Center for Chronic Diseases, ACCDiS, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

María Isabel Rodríguez, Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, Paraguay.

Yessy Cabrera, Instituto de Investigaciones en Microbiología, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras.

Brenda Salgado, Secretaría de Salud, Tegucigalpa, Honduras.

María Celeste Colucci, Instituto Nacional de Enfermedades Infecciosas - ANLIS Malbrán, Buenos Aires, Argentina.

Maria Agustina Saino, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina.

Margarita Rodríguez de la Peña, Hospital Nacional Profesor Alejandro Posadas, Buenos Aires, Argentina

Daniel Llanos Fernández, Facultad de Medicina, Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca, Sucre, Bolivia

Laura García, Laboratorio de Biología Molecular, Departamento de Patología Clínica, Centro Hospitalario Pereira Rossell, Montevideo, Uruguay.

Benedicta Caserta, Departamento de Anatomía Patológica y Citología, Hospital de la Mujer, Centro Hospitalario Pereira Rossell, Montevideo, Uruguay

Gloria Inés Sánchez, Grupo de Infección y Cáncer, Facultad de Medicina, Universidad de Antioquía, Medellín, Colombia

Franco Doimi, Patología Oncológica SAC, Lima, Perú.

Eduardo Lazcano-Ponce, Instituto de Salud Pública de México, Morelos, México.